Clinical Trial Update: Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas [Phase 3]

View source ↗

Summary

This Phase 3 trial is evaluating whether adding immunotherapy to chemotherapy improves outcomes versus chemotherapy alone in patients with aggressive poorly dif…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dedifferentiated Liposarcoma
• Soft Tissue Sarcoma of the Trunk and Extremities
• Undifferentiated Pleomorphic Sarcoma
• Unresectable Dedifferentiated Liposarcoma
• Unresectable Undifferentiated Pleomorphic Sarcoma

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma | Phase 3 | Status: RECRUITING